ResearcherLoma Linda UniversityNo recent work listed

Samrat M. Sanghvi

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5028163267. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2022: 1 paper

Papers 1

A phase II trial of gemcitabine and erlotinib followed by ChemoProton therapy plus capecitabine and oxaliplatin for locally advanced pancreatic cancer. Co-author DOI 10.21037/jgo-22-327 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Alex Coffman · 1 shared paper, 2022 · strength 0.15
- Paper A phase II trial of gemcitabine and erlotinib followed by ChemoProton therapy plus capecitabine and oxaliplatin for loc… DOI 10.21037/jgo-22-327 ↗
Gary Yang · 1 shared paper, 2022 · strength 0.15
- Paper A phase II trial of gemcitabine and erlotinib followed by ChemoProton therapy plus capecitabine and oxaliplatin for loc… DOI 10.21037/jgo-22-327 ↗
Chung-Tsen Hsueh · 1 shared paper, 2022 · strength 0.15
- Paper A phase II trial of gemcitabine and erlotinib followed by ChemoProton therapy plus capecitabine and oxaliplatin for loc… DOI 10.21037/jgo-22-327 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.